Search results
Showing 8131 to 8145 of 8901 results
Intramedullary distraction for lower limb lengthening (IPG197)
This guidance has been updated and replaced by NICE HealthTech guidance 613.
In development Reference number: GID-TA11491 Expected publication date: TBC
In development Reference number: GID-TA11511 Expected publication date: TBC
In development Reference number: GID-TA11406 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)
This guidance has been updated and replaced by NICE technology appraisal 217.
Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)
This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314].
This guidance has been updated and replaced by NICE technology appraisal guidance 243.
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657
Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)
We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.
The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)
This guidance has been updated and replaced by NICE guideline CG43.
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)
This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.
This guidance has been updated and replaced by NICE technology appraisal guidance 604.
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)
This guidance has been updated and replaced by NICE technology appraisal guidance 752.